HC Wainwright reissued their buy rating on shares of Daré Bioscience (NASDAQ:DARE – Free Report) in a research note published on Thursday morning, Benzinga reports. They currently have a $12.00 price objective on the biotechnology company’s stock.
Separately, Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.
Get Our Latest Research Report on Daré Bioscience
Daré Bioscience Trading Up 0.3 %
Daré Bioscience (NASDAQ:DARE – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $2.09. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.60 million. Equities research analysts forecast that Daré Bioscience will post -0.27 earnings per share for the current year.
Institutional Investors Weigh In On Daré Bioscience
An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC grew its position in shares of Daré Bioscience, Inc. (NASDAQ:DARE – Free Report) by 2.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the SEC. Institutional investors own 6.70% of the company’s stock.
Daré Bioscience Company Profile
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
See Also
- Five stocks we like better than Daré Bioscience
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- What is the S&P 500 and How It is Distinct from Other Indexes
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.